Elutia to Showcase Anti-Infection Tech at LD Micro Invitational
Event summary
- Elutia CEO Dr. Randy Mills and CFO Matt Ferguson will present at the 16th Annual LD Micro Invitational on May 18, 2026.
- The company will discuss its drug-eluting biomatrix technology for reducing post-surgical infections in implant-based breast reconstruction.
- One-on-one investor meetings will be held the same day.
- The presentation begins at 11:30 am Pacific Time and will be available via webcast.
The big picture
Elutia's focus on reducing post-surgical infections in implant-based breast reconstruction aligns with broader industry efforts to improve patient outcomes in reconstructive surgery. The company's participation in the LD Micro Invitational underscores its push to engage with micro-cap investors as it seeks to expand its market presence. Success in this niche could position Elutia as a key player in the growing demand for safer implantable technologies.
What we're watching
- Technology Validation
- How Elutia's presentation will position its drug-eluting biomatrix technology against existing solutions in the implant-based breast reconstruction market.
- Investor Sentiment
- Whether the one-on-one meetings will generate renewed interest or skepticism among investors regarding Elutia's commercialization strategy.
- Market Expansion
- The pace at which Elutia can scale its technology to address other high-risk surgical infections beyond breast reconstruction.
Related topics